NKTR Earnings

NKTR reported its FY2025Q4 earnings on 2026-03-03, showcasing a revenue of against an estimate of 9.57M, resulting in a 0% surprise. The EPS was 0, surpassing the expected -2.69 by 0% . The stock experienced a 0% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following NKTR's FY2025Q4 earnings announcement on 2026-03-03, the stock price moved by % on the day of the release. Over the subsequent five days, it saw a % change. Historically, NKTR's stock price tends to shift by an average of -6.10% in the 10 days leading up to earnings and -3.03% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate NKTR’s annual revenue to reach 10.43M, while the EPS is projected at -2.42. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Upward by 0.01% and EPS estimates Revise Upward by 1.39% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between NKTR's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were Revise Upward by 0.01%, while EPS estimates moved Revise Upward by 1.39% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, NKTR's stock price typically moves by -6.10% in the 10 days before its earnings and -3.03% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of -2.42 and revenue of 10.43M.

Despite some unclear management responses, the earnings call highlights strong market opportunities for REZPEG, particularly in atopic dermatitis and alopecia areata. The company's financial guidance shows a healthy cash runway, and the potential differentiation of REZPEG from competitors is promising. The Q&A section reveals significant interest in REZPEG's unique mechanism and its potential safety advantages over JAK inhibitors. Overall, these factors suggest a positive sentiment towards Nektar's future prospects, supporting a positive stock price movement prediction.